Guangdong Bisutang Biotechnology Co., Ltd.
3 extracted findings
FDA source excerpt, selected passage
This request went unanswered as did numerous follow-up requests, including a second electronic request sent on May 19, 2026, and a separate phone call to the listed U.S. Agent of record on May 27, 2026.
Findings and supporting evidence
Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.
Findings extracted from the letter
Selected FDA passages, not the complete letter.
01
This request went unanswered as did numerous follow-up requests, including a second electronic request sent on May 19, 2026, and a separate phone call to the listed U.S. Agent of record on May 27, 2026.
Source passage selected by the model
02
your “XUEYI SKIN CARE” sunscreen drug product contains the cancelled color additive CI 11680 (also known as Ext. D&C Yellow No. 5***1***).
Source passage selected by the model
03
there appear to be discrepancies in the electronic import entry submissions for your products, specifically regarding the failure to correctly declare your drug product listing.
Source passage selected by the model
Sections and clauses cited
As cited in this historical letter, not a statement of current regulatory requirements.